ABC | Volume 111, Nº6, Dezembro 2018

Artigo Original Einwoegerer e Domingueti Cistatina C e evento cardiovascular ou mortalidade Arq Bras Cardiol. 2018; 111(6):796-807 1. Organização Pan Americana de Saúde. (OPAS-OMS). [Internet]. [Acesso em 2018 abr 10]. Disponível em: https://www.paho.org/bra/ index.php?option=com_content&view=article&id=5253:doencas- cardiovasculares&Itemid=839 2. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al; European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practive (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10(4):S1-10. 3. Bi M, Huang Z, Li P, Cheng C, Huang Y, Chen W. The association between elevated cystatin C levels with myocardial infarction: a meta-analysis. Int J Clin Exp Med. 2015:8(11):20540-7. 4. Wang M, Zhang L, Yue R, You G, Zeng R. Significance of cystatin C for early diagnosis of contrast-induced nephropathy in patients undergoing coronary angiography. Med Sci Monit. 2016;22:2956-61. 5. Lameire N, Vanholder R, Biesen WV, Benoit D. Acute kidney injury in critically ill cancer patients: an update. Crit Care. 2016;20(1):209. 6. Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection. Hypertension. 2004;43(4):e14. 7. AbidL,CharfeddineS,KammounS,TurkiM,AyediF.CystatinC:aprognostic marker after myocardial infarction in patients without chronic kidney disease. J Saudi Heart Assoc. 2016;28(3):144-51. 8. Dupont M, Wu Y, Hazen SL, Tang WH. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ. Heart failure. 2012;5(5):602-9. 9. LiR,HaoP,ChenY,ZhangY.AssociationofcystatinC levelandcardiovascular prognosis for patients with preexisting coronary heart disease: a meta- analysis. Chin Sci Bulletin. 2014;59(5-6):539-45. 10. Bi M, Huang Z, Li P, Cheng C, Huang Y, Chen W. The association between elevated cystatin C levels with myocardial infarction: a meta-analysis. Int J Clin Exp Med. 2015;8(11):20540-7. 11. Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: ameta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3(6):675-83. 12. Luo J, Wang LP, Hu HF, Zhang L, Li YL, Ai LM, et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: a meta- analysis. Clin Chim Acta. 2015 Oct 23;450:39-45. 13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. 14. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analysis [Internet]. [Access in 2017 Sep 1]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 15. Bansal N, Lin F, Vittinghoff E, Peralta C, Lima J, Kramer H, et al. Estimated GFR and subsequent higher left ventricular mass in young andmiddle-aged adults with normal kidney function: the coronary artery risk development in young adults (CARDIA) study. Am J Kidney Dis. 2016;67(2):227-34. 16. García Acuña JM, González-Babarro E, Grigorian Shamagian L, Peña-Gil C, Vidal Pérez R, López-Lago AM, et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol. 2009;62(5):510-9. 17. KellerT,MartinaCM,LubosE,NicaudV,WildSP,RupprechtHJ,etal.Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J. 2009;30(3):314-20. 18. Woitas RP, Kleber ME, Meinitzer A, Grammer TB, Silbernagel G, Pilz Stefan, et al. Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis. 2013;229(2):541-8. 19. Sai E, Shimada K, Miyauchi K, Masaki Y, Kojima T, Miyazaki T, et al. Increased cystatinClevelsasariskfactorofcardiovasculareventsinpatientswithpreserved estimated glomerular filtration rate after elective percutaneous coronary interventionwith drug‑eluting stents. Heart Vessels. 2016;31(5):694-701. 20. AlehagenU, DahlströmU, Lindahl TL. CystatinC andNT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11(4):354-60. 21. GaoC, Zhong L, Gao Y, Li X, ZhangM,Wei S. CystatinC levels are associated with the prognosis of systolic heart failure patients. Arch Cardiovasc Dis. 2011;104(11):565-71. 22. Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol. 2009;32(11):644-8. 23. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of Cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease data from the Heart and Soul Study. Circulation. 2007;115(2):173-9. 24. KoeningW. Is elevated cystatin C a predictor of cardiovascular risk in elderly people without chronic kidney disease? Nat Clin Pract Cardiovasc Med. 2007;4(2):76-7. 25. Guyton AC, Hall JE. Tratado de Fisiologia Médica. 12ª. ed. Rio de Janeiro: Elsevier; 2011. p. 870-1. 26. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(8):1359-66. 27. Eriksson P, Jones KG, Brown LC, Greenhalgh RM, Hamsten A, Powell JT. Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms. Br J Surg. 2004;91(1):86-9. 28. Prates AB, Amaral FB, Vacaro MZ, Gross JL, Camargo JL, Silveiro SP. Glomerular filtration evaluation employing serum cystatin Cmeasurement. J Bras Nefrol. 2013;35(1):48-56. 29. Gabriel IC, Nishida SK, Kirsztajn GM. [Serum cystatin C: a practical alternative for renal function evaluation?] J Bras Nefrol. 2011;33(2):261-7. 30. Moura RS. Cistatina C em pacientes com hipertensão arterial essencial: Avaliação da função renal e correlação com fatores de risco cardiovascular [Dissertação]. Brasília: Universidade de Brasília; 2010. 31. Porto JR, Gomes KB, Fernandes AP, Domingueti CP. Avaliação da função renal na doença renal crônica. RBAC. 2017;49(1):26-35. 32. Pucci L, Triscorna S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimatives of renal function: searching a better measure of kidney function in diabetic patients. Clin Chem. 2007;53(3):480-8. 33. Le Bricon T, Thervet E, Froissart M, Benlakehal M, Bousquet B, Legendre C, et al. Plasma cystatin C is superior to 24 h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. Clin Chem. 2000;46(8 Pt 1):1206-7. Referências 806